JP2009512635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512635A5 JP2009512635A5 JP2008532866A JP2008532866A JP2009512635A5 JP 2009512635 A5 JP2009512635 A5 JP 2009512635A5 JP 2008532866 A JP2008532866 A JP 2008532866A JP 2008532866 A JP2008532866 A JP 2008532866A JP 2009512635 A5 JP2009512635 A5 JP 2009512635A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- convertible
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 206010057668 Cognitive disease Diseases 0.000 claims 3
- -1 chloro, bromo, fluoro, methyl Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 230000003551 muscarinic Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- KRRSQJOVDWYKHH-UHFFFAOYSA-N 7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound C12=CC(C)=CC(F)=C2NC(=O)N1C(CC1)CCN1C1CCOCC1 KRRSQJOVDWYKHH-UHFFFAOYSA-N 0.000 claims 2
- 206010061284 Mental disease Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000001808 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000012442 inert solvent Substances 0.000 claims 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- DSUMPQPZYPXTND-UHFFFAOYSA-N 5-chloro-7-fluoro-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=C1NC=2C(F)=CC(Cl)=CC=2N1C(CC1)CCN1C1CCOCC1 DSUMPQPZYPXTND-UHFFFAOYSA-N 0.000 claims 1
- YFCGENMQCIXTNC-UHFFFAOYSA-N 5-cyclopropyl-7-fluoro-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=C1NC=2C(F)=CC(C3CC3)=CC=2N1C(CC1)CCN1C1CCOCC1 YFCGENMQCIXTNC-UHFFFAOYSA-N 0.000 claims 1
- KQYDZKAMMFFLSN-UHFFFAOYSA-N 6,7-difluoro-5-methyl-3-[1-(4-methyloxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=C1NC=2C(F)=C(F)C(C)=CC=2N1C(CC1)CCN1C1(C)CCOCC1 KQYDZKAMMFFLSN-UHFFFAOYSA-N 0.000 claims 1
- UHCMVLUHZXKNJQ-UHFFFAOYSA-N 6,7-difluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=C1NC=2C(F)=C(F)C(C)=CC=2N1C(CC1)CCN1C1CCOCC1 UHCMVLUHZXKNJQ-UHFFFAOYSA-N 0.000 claims 1
- NCIMFRCDQMTAFP-UHFFFAOYSA-N 7-fluoro-5-methoxy-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound C12=CC(OC)=CC(F)=C2NC(=O)N1C(CC1)CCN1C1CCOCC1 NCIMFRCDQMTAFP-UHFFFAOYSA-N 0.000 claims 1
- DQSNUMFLMIZQFH-UHFFFAOYSA-N 7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C12=CC(C)=CC(F)=C2NC(=O)N1C(CC1)CCN1C1CCOCC1 DQSNUMFLMIZQFH-UHFFFAOYSA-N 0.000 claims 1
- FDACQSJDRGVKFF-UHFFFAOYSA-N 7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one;hydrochloride Chemical group Cl.C12=CC(C)=CC(F)=C2NC(=O)N1C(CC1)CCN1C1CCOCC1 FDACQSJDRGVKFF-UHFFFAOYSA-N 0.000 claims 1
- KJCKZWGVZMJOCI-UHFFFAOYSA-N 7-fluoro-5-methyl-3-[1-(oxan-4-yl)piperidin-4-yl]-1H-benzimidazol-2-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.C12=CC(C)=CC(F)=C2NC(=O)N1C(CC1)CCN1C1CCOCC1 KJCKZWGVZMJOCI-UHFFFAOYSA-N 0.000 claims 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 claims 1
- 238000003747 Grignard reaction Methods 0.000 claims 1
- 239000007818 Grignard reagent Substances 0.000 claims 1
- 238000006751 Mitsunobu reaction Methods 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002829 reduced Effects 0.000 claims 1
- 238000005932 reductive alkylation reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000008096 xylene Substances 0.000 claims 1
- 0 Cc(c(*)c1*)cc(N2C(CC3)CCN3C3(*)CCOCC3)c1NC2=O Chemical compound Cc(c(*)c1*)cc(N2C(CC3)CCN3C3(*)CCOCC3)c1NC2=O 0.000 description 1
Claims (19)
- 式(I):
R4はフルオロであり;
R5は、水素、ハロゲン、シアノ、C1-6アルキル、1個またはそれ以上のフッ素原子で置換されているC1-6アルキル、C1-6アルコキシ、および1個またはそれ以上のフッ素原子で置換されているC1-6アルコキシから選択され;
R6は、ハロゲン、シアノ、C1-6アルキル、1個またはそれ以上のフッ素原子で置換されているC1-6アルキル、C3-6シクロアルキル、1個またはそれ以上のフッ素原子で置換されているC3-6シクロアルキル、C1-6アルコキシ、および1個またはそれ以上のフッ素原子で置換されているC1-6アルコキシから選択され、
Qは、水素またはC1-6アルキルである]
で示される化合物またはその塩もしくは溶媒和物。 - R5が、水素、クロロ、ブロモ、フルオロ、C1-4アルキル、1個またはそれ以上のフッ素原子で置換されているC1-4アルキル、およびC1-4アルコキシから選択される、請求項1記載の化合物。
- R6が、クロロ、ブロモ、フルオロ、メチル、エチル、イソプロピル、シクロプロピル、メトキシ、トリフルオロメトキシおよびトリフルオロメチルから選択される、請求項1または2記載の化合物。
- Qが水素およびメチルから選択される、請求項1〜3いずれか1項記載の化合物。
- 4−フルオロ−6−メチル−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン、
6−クロロ−4−フルオロ−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン、
4−フルオロ−6−メトキシ−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン、
4,5−ジフルオロ−6−メチル−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン、
6−シクロプロピル−4−フルオロ−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン、
4,5−ジフルオロ−6−メチル−1−[1−(4−メチルテトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン
および
それらの塩および溶媒和物
からなる群から選択される請求項1記載の化合物。 - 請求項1〜5いずれか1項記載の化合物、および医薬上許容される担体を含む医薬組成物。
- 治療用の請求項1〜5いずれか1項記載の化合物。
- ムスカリンM1受容体のアゴニズムを要する状態の治療用の請求項1〜5いずれか1項記載の化合物。
- 精神障害または認知障害の治療用の請求項1〜5いずれか1項記載の化合物。
- ムスカリンM1受容体のアゴニズムを要する状態の治療薬の製造における請求項1〜5いずれか1項記載の化合物の使用。
- 精神障害または認知障害の治療薬の製造における請求項1〜5いずれか1項記載の化合物の使用。
- 請求項1〜5いずれか1項記載の化合物を含む、ムスカリンM 1 受容体のアゴニズムを要する状態の治療のための医薬組成物。
- 請求項1〜5いずれか1項記載の化合物を含む、精神障害または認知障害の治療のための医薬組成物。
- 以下の方法から選択される、請求項1で定義した式(I)で示される化合物またはその塩もしくは溶媒和物の製造方法:
還元的アルキル化に適した条件下で、式(II):
および
シアニド源の存在下にて式(II)で示される化合物を式(III)で示される化合物と反応させて、シアノ中間体(XXXX)を形成することを含み、それをグリニャール反応に適した条件下にてアルキルグリニャール試薬QMgXと反応させて式(I)で示される化合物を形成することができる方法(A2):
および
不活性溶媒中であってもよく、塩基の存在下であってもよく、加熱しながらであってもよく、式(IV):
および
式(VI):
および
式(VIII):
および
式(X):
および
アルキル化またはミツノブ反応条件下にて式(XI):
および、その後、上記の方法のいずれかについて、
いずれもの保護基を除去してもよいこと;および/または
式(I)で示される化合物またはその塩もしくは溶媒和物を式(I)で示される別の化合物またはその塩もしくは溶媒和物へ変換してもよいこと。 - 式(II):
式(XXXX):
式(IV):
式(VI):
または
式(X):
- 4−フルオロ−6−メチル−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オンである請求項1記載の化合物。
- 4−フルオロ−6−メチル−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン・塩酸塩である請求項1記載の化合物。
- 4−フルオロ−6−メチル−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン・一クエン酸塩である請求項1記載の化合物。
- 4−フルオロ−6−メチル−1−[1−(テトラヒドロ−2H−ピラン−4−イル)−4−ピペリジニル]−1,3−ジヒドロ−2H−ベンゾイミダゾール−2−オン・メタンスルホン酸塩である請求項1記載の化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0519950.0 | 2005-09-30 | ||
GBGB0519950.0A GB0519950D0 (en) | 2005-09-30 | 2005-09-30 | Compounds |
GB0602040.8 | 2006-02-01 | ||
GB0602040A GB0602040D0 (en) | 2006-02-01 | 2006-02-01 | Compounds |
PCT/GB2006/003590 WO2007036715A2 (en) | 2005-09-30 | 2006-09-27 | Compounds which have activity at m1 receptor and their uses in medicine |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009512635A JP2009512635A (ja) | 2009-03-26 |
JP2009512635A5 true JP2009512635A5 (ja) | 2009-11-12 |
JP5209480B2 JP5209480B2 (ja) | 2013-06-12 |
Family
ID=37598231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008532866A Expired - Fee Related JP5209480B2 (ja) | 2005-09-30 | 2006-09-27 | M1受容体にて活性を有する化合物および医薬におけるそれらの使用 |
Country Status (24)
Country | Link |
---|---|
US (2) | US8283364B2 (ja) |
EP (1) | EP1943230B1 (ja) |
JP (1) | JP5209480B2 (ja) |
KR (2) | KR20130091791A (ja) |
CN (1) | CN101321736B (ja) |
AR (1) | AR056103A1 (ja) |
AT (1) | ATE492537T1 (ja) |
AU (1) | AU2006296369B2 (ja) |
BR (1) | BRPI0616609A2 (ja) |
CA (1) | CA2624504C (ja) |
CR (1) | CR9904A (ja) |
DE (1) | DE602006019119D1 (ja) |
EA (1) | EA016286B1 (ja) |
IL (1) | IL190219A (ja) |
JO (1) | JO2634B1 (ja) |
MA (1) | MA29849B1 (ja) |
MY (1) | MY148504A (ja) |
NO (1) | NO20081945L (ja) |
NZ (1) | NZ566508A (ja) |
PE (1) | PE20070490A1 (ja) |
TW (1) | TWI389905B (ja) |
UA (1) | UA101299C2 (ja) |
WO (1) | WO2007036715A2 (ja) |
ZA (1) | ZA200802167B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007036715A2 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
US8288413B2 (en) * | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
EP1960389B1 (en) | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0718415D0 (en) | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
WO2009124882A1 (en) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists |
GB0817982D0 (en) | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
US20170333407A1 (en) * | 2014-11-03 | 2017-11-23 | William Beaumont Hospital | Method for treating underactive bladder syndrome |
ES2767707T3 (es) * | 2015-04-29 | 2020-06-18 | Janssen Pharmaceutica Nv | Compuestos de indolona y su uso como moduladores de receptor AMPA |
SG11201708190UA (en) | 2015-04-29 | 2017-11-29 | Janssen Pharmaceutica Nv | Azabenzimidazoles and their use as ampa receptor modulators |
WO2017044693A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
CN107673994A (zh) * | 2017-04-27 | 2018-02-09 | 联化科技股份有限公司 | 一种芳基甲烷类化合物的制备方法 |
CN107739342B (zh) * | 2017-11-29 | 2020-01-10 | 华南理工大学 | 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法 |
CN117049938B (zh) * | 2023-06-20 | 2024-06-14 | 山东轩德医药科技有限公司 | 一种6-溴-2,3-二氟甲苯的制备方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3161645A (en) * | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
US3989707A (en) * | 1974-06-21 | 1976-11-02 | Janssen Pharmaceutica N.V. | Benzimidazolinone derivatives |
US4292321A (en) | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
DE3124366A1 (de) | 1981-06-20 | 1982-12-30 | Hoechst Ag, 6000 Frankfurt | N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
JP3916093B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
US5574044A (en) | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
EP0786997A4 (en) * | 1994-10-27 | 1998-03-11 | Merck & Co Inc | MUSCARINE ANAGONISTS |
AU7478396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine agonists |
US5718912A (en) | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO1999032481A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
ES2223588T3 (es) | 1999-10-13 | 2005-03-01 | Banyu Pharmaceutical Co., Ltd. | Derivados de imidazolidinona sustituidos. |
SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
WO2001057019A1 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
JP4401076B2 (ja) | 2001-04-18 | 2010-01-20 | ユーロ−セルティーク エス.エイ. | ベンズイミダゾロン化合物 |
CA2444595A1 (en) * | 2001-04-20 | 2002-10-31 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
KR100809569B1 (ko) | 2001-10-02 | 2008-03-04 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 제제로서 벤즈이미다졸리디논 유도체 |
US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
ES2392340T3 (es) | 2002-03-29 | 2012-12-07 | Mitsubishi Tanabe Pharma Corporation | Remedio para los trastornos del sueño |
WO2003105781A2 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
RU2005118407A (ru) | 2002-12-13 | 2006-03-10 | СмитКлайн Бичем Корпорейшн (US) | Производные пиперидина в качестве антагонистов ccr5 |
JP2005102133A (ja) | 2003-04-28 | 2005-04-14 | Ricoh Co Ltd | 画像形成装置及び宛先情報参照方法 |
CN1823062A (zh) | 2003-07-23 | 2006-08-23 | 惠氏公司 | 作为5-羟色胺-6配体的磺酰基二氢苯并咪唑酮化合物 |
AP2184A (en) | 2003-09-03 | 2010-12-02 | Pfizer | Benzimidazolone compounds having 5-HT4 receptor agonistic activity. |
MX2007005290A (es) | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
EP1960389B1 (en) | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
US8288413B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Benzimidazolones which have activity at M1 receptor |
WO2007036715A2 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
AU2007292997A1 (en) | 2006-09-08 | 2008-03-13 | The Gillette Company | Toothbrush with multiple bristle states |
GB0706173D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706190D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706187D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706167D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706189D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706170D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706164D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706165D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706188D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-09-27 WO PCT/GB2006/003590 patent/WO2007036715A2/en active Application Filing
- 2006-09-27 EA EA200801001A patent/EA016286B1/ru not_active IP Right Cessation
- 2006-09-27 EP EP06794584A patent/EP1943230B1/en active Active
- 2006-09-27 CN CN2006800451692A patent/CN101321736B/zh not_active Expired - Fee Related
- 2006-09-27 KR KR1020137020049A patent/KR20130091791A/ko not_active Application Discontinuation
- 2006-09-27 BR BRPI0616609-1A patent/BRPI0616609A2/pt not_active IP Right Cessation
- 2006-09-27 DE DE602006019119T patent/DE602006019119D1/de active Active
- 2006-09-27 US US12/088,465 patent/US8283364B2/en not_active Expired - Fee Related
- 2006-09-27 CA CA2624504A patent/CA2624504C/en not_active Expired - Fee Related
- 2006-09-27 AU AU2006296369A patent/AU2006296369B2/en not_active Ceased
- 2006-09-27 NZ NZ566508A patent/NZ566508A/en not_active IP Right Cessation
- 2006-09-27 KR KR1020087007797A patent/KR101374458B1/ko not_active IP Right Cessation
- 2006-09-27 JP JP2008532866A patent/JP5209480B2/ja not_active Expired - Fee Related
- 2006-09-27 AT AT06794584T patent/ATE492537T1/de not_active IP Right Cessation
- 2006-09-27 MY MYPI20080901A patent/MY148504A/en unknown
- 2006-09-27 UA UAA200803937A patent/UA101299C2/uk unknown
- 2006-09-28 PE PE2006001183A patent/PE20070490A1/es not_active Application Discontinuation
- 2006-09-28 TW TW095135887A patent/TWI389905B/zh not_active IP Right Cessation
- 2006-09-28 AR ARP060104268A patent/AR056103A1/es unknown
- 2006-09-28 JO JO2006342A patent/JO2634B1/en active
-
2007
- 2007-09-10 US US11/852,455 patent/US8481566B2/en not_active Expired - Fee Related
-
2008
- 2008-03-17 IL IL190219A patent/IL190219A/en not_active IP Right Cessation
- 2008-04-04 MA MA30812A patent/MA29849B1/fr unknown
- 2008-04-18 CR CR9904A patent/CR9904A/es unknown
- 2008-04-23 NO NO20081945A patent/NO20081945L/no not_active Application Discontinuation
-
2009
- 2009-03-07 ZA ZA200802167A patent/ZA200802167B/xx unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009512635A5 (ja) | ||
JP2009510041A5 (ja) | ||
JP2009510037A5 (ja) | ||
CA2624504A1 (en) | Benzimidazolone compounds which have activity at m1 receptor and their uses in medicine | |
JP4357965B2 (ja) | メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピロールモジュレーター | |
JP5313865B2 (ja) | ベンゾイミダゾール化合物およびその医薬用途 | |
JP4299139B2 (ja) | 代謝型グルタミン酸受容体−5のヘテロアリール置換トリアゾールモジュレータ | |
AU2023201399A1 (en) | Modulators of the integrated stress pathway | |
AU2015335703B2 (en) | Carbazole derivatives | |
JP5209481B2 (ja) | M1受容体にて活性を有する化合物および医薬におけるそれらの使用 | |
WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
JP2011500758A5 (ja) | ||
JP2006510716A5 (ja) | ||
JP2009530348A5 (ja) | ||
RU2005104434A (ru) | Производные 1-гетероциклилалкил-3-сульфонилиндола или - индазола как лиганды 5-гидрокситриптамина-6 | |
JP2009538910A5 (ja) | ||
TWI244472B (en) | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds | |
JP2005526081A (ja) | 代謝型グルタメート−5の二アリール置換テトラゾールモジュレータ | |
CA2991572A1 (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
JP2012507525A5 (ja) | ||
JP2006522137A (ja) | 代謝型グルタミン酸受容体−5のジ−アリール置換ピロールモジュレーター | |
JP4493648B2 (ja) | オピオイド受容体拮抗薬としての2‐アザビシクロ(3.3.1)ノナン誘導体 | |
WO2004087653A2 (en) | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 | |
JPWO2003095432A1 (ja) | ベンズイミダゾール誘導体 | |
JP2009513513A (ja) | Orl−1受容体リガンドとしての置換インドール |